Last updated: February 13, 2026
What Is the Current Market Status of the Drug NDC 70677-1110?
NDC 70677-1110 corresponds to Tafasitamab with Lenalidomide, indicated for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients not eligible for autologous stem cell transplant. Approved by the FDA in August 2020, the drug has established a niche in hematologic oncology.
How Does the Market for Tafasitamab with Lenalidomide Evolve?
Patient Population and Market Penetration
- Target Population: Predominantly relapsed/refractory DLBCL patients ineligible for transplant, estimated at approximately 20,000 annual cases in the U.S.
- Market Penetration:
- Early adoption peaked in 2021-2022, capturing about 10% of eligible patients.
- Competition primarily from CAR T-cell therapies (e.g., Axicabtagene Ciloleucel), which dominate second-line treatment in eligible patients.
- Market share remains constrained by treatment positioning; Tafasitamab is used post-chemotherapy failure in non-transplant candidates.
Revenue Estimates
| Year |
Estimated U.S. Sales (USD millions) |
Notes |
| 2022 |
150-200 |
Early adopters, constrained by market share |
| 2023 |
180-220 |
Slight growth as awareness increases |
| 2024 |
200-250 |
Expansion due to clinical adoption |
- Orphan drug designation reduces development costs and extends exclusivity by 7 years, potentially supporting higher pricing.
Global Perspective
- Currently, limited international sales because of regulatory approval pending in Europe and other markets.
- Anticipated launches in select European countries between 2024-2025 could expand global revenue.
What Are the Price Trends and Forecasts for NDC 70677-1110?
Pricing Dynamics
- Average Wholesale Price (AWP): Approximately $12,000 to $14,000 per infusion, with a typical treatment course comprising 3-6 infusions.
- List Price (2019-2022): Around $36,000 to $84,000 per treatment course, depending on dosing regimens.
- Reimbursement Environment: Payers are increasingly negotiating discounts; average net price could be 10-15% below list price.
Price Projections
- Short-term (2023-2025): Marginal increases in list prices, driven by inflation and manufacturing costs. Slight discounts expected due to payer pressure.
- Mid-term (2026-2030): Potential for price stabilization or modest reductions, contingent on new competitors or biosimilars entry.
- Impact of Biosimilars: No biosimilar currently available; however, biosimilar development could place downward pressure by 2028-2030.
How Will Market Influences Shape Revenue and Price?
Regulatory and Competitive Factors
- Regulatory Approvals: Pending in Europe and other jurisdictions could boost global revenue.
- Market Competition: Increased use of CAR T-cell therapies limits growth; however, Tafasitamab remains relevant for non-eligible patients.
- Potential New Indications: Trials for other B-cell malignancies could expand market size, impacting revenue.
Pricing Policy and Reimbursement
- Insurance coverage increasingly favors value-based pricing.
- Payer restrictions could influence the maximum reimbursable price, especially if biosimilars or alternative therapies enter the market.
Key Takeaways
- The drug has a niche in relapsed/refractory DLBCL, with current U.S. sales projections of approximately $200 million annually.
- Market penetration remains limited by alternative therapies and treatment guidelines.
- Price per treatment course ranges mainly between $36,000 and $84,000, with potential slight increases constrained by payer negotiations.
- Expanding international approval and development of biosimilars may influence future sales volume and pricing.
- The outlook involves gradual growth, largely dependent on regulatory decisions, market adoption, and competitive dynamics.
FAQs
1. How does Tafasitamab with Lenalidomide compare to CAR T-cell therapies?
CAR T therapies are generally more effective in eligible patients, offering higher response rates and durability. Tafasitamab primarily targets patients ineligible for transplant or CAR T, filling a treatment gap.
2. Are there plans to expand indications for this drug?
Clinical trials are ongoing in marginal zone lymphoma and other B-cell malignancies, which could broaden the market.
3. What are the main barriers to growth for this drug?
Limited eligibility due to competing therapies, reimbursement pressures, and potential biosimilar entry limit growth.
4. What is the likelihood of biosimilar development?
Biosimilars could be developed by multiple manufacturers within 3-5 years, but complex manufacturing may delay entry.
5. How might pricing evolve in response to market pressures?
Prices are likely to stabilize with minor adjustments, influenced by payer negotiations and biosimilar competition.
Sources:
[1] FDA Approval Announcement, August 2020
[2] MarketResearch.com, Hematologic Malignancies Market Outlook 2023
[3] IQVIA Databases, US Oncology Sales Data 2022-2023
[4] Industry Reports, Biotech Market Trends 2023
